Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
You may also be interested in...
Revlimid Data Could Support First-Line Use In Multiple Myeloma
Higher survival rate is seen with Revlimid in combination with lower-dose dexamethasone compared to use with a higher dose of the steroid.
Revlimid Data Could Support First-Line Use In Multiple Myeloma
Higher survival rate is seen with Revlimid in combination with lower-dose dexamethasone compared to use with a higher dose of the steroid.
Biogen Idec Initiates Pivotal Lumiliximab CLL Trial
Company tells “The Pink Sheet” DAILY it hopes for a 2009 launch of the chronic lymphocytic leukemia therapy.